Dimethyl Sulfoxide as an Excitatory Modulator and its Possible Role in Cancer Pain Management
Dimethyl sulfoxide (DMSO) is a naturally derived, inexpensive, non-toxic solvent and pharmaceutical agent that has been demonstrated to have numerous health enhancing and therapeutic benefits. In the present article, we provide the scientific evidence and substantiate possible application of DMSO as a well-tolerated excitatory modulator in the management of cancer pain.
Keywords: Cancer pain; Dimethyl Sulfoxide (DMSO); Dimethyl sulfoxide; Dimethyl sulfoxide (DMSO); N-methyl-D-aspartate (NMDA); Sodium channel (SC); amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA); analgesic therapy; antiarrhythmic; antiepileptic; cachexia; calcium influx; cancer; cell membrane hyperexcitability; chemotherapy; cryoprotectant; edema; hemoglobinuria; hepatotoxicity; hyperalgesia; hyperexcitability; ketamine; metastases; nephrotoxicity; neuropathic pain; nociceptive; opioids; pain; psychomimetic effects; radiation therapy; raspberries; sodium channel blocker; sodium channels; sodium channels (SC); spinal nerve ligation, spinal nerve transection; surgery; tetrodotoxin; traumatic brain injury
Document Type: Research Article
Publication date: September 1, 2010
- Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites